Product Search

  • Arthritic Pain - 2005
    Pharmacor, November, 2005

    Will emerging drugs replace the once-lucrative cyclooxygenase-2 (COX-2) inhibitors? Will any of the COX-2 inhibitors now in development overcome the regulatory...

  • Postoperative Pain - 2006
    Pharmacor, May, 2006

    Surprisingly, given the short treatment period for

    postoperative pain, drug sales in this market reached $5.7 billion in 2004, a

    much...

  • Acute Myeloid Leukemia - 2006
    Pharmacor, October, 2006

    Acute myeloid leukemia (AML, also know as acute myelogenous
    leukemia) is largely a disease of adults, with the majority of cases occurring
    in people...

  • Restless Legs Syndrome - 2006
    Pharmacor, November, 2006

    Interest in restless legs syndrome (RLS) has recently grown.

    However, sales of approved agents are small because of low diagnosis rates.

  • Acute Lymphoblastic Leukemia - 2006
    Pharmacor, November, 2006

    Acute lymphoblastic leukemia (ALL) is associated with a low
    disease incidence and highly diverse biology. These characteristics generate
    small...

  • Insomnia - 2007
    Pharmacor, August, 2007

    With a prevalent population of more than 140 million

    individuals, steadily growing diagnosis and drug-treated rates, and a small

    number...

  • Managing the Side Effects of Chemotherapy - 2007
    Pharmacor, November, 2007

    Major-market sales for the most common side effects of

    chemotherapy (anemia, neutropenia, thrombocytopenia, chemotherapy-induced

    nausea...

  • Cognitive Dysfunction - 2008
    Pharmacor, January, 2008

    Cognitive dysfunction is a highly prevalent and disabling
    condition. However, with no approved—or proven—therapies, diagnosis rates are
    low and drug...

  • Atopic Dermatitis - 2008
    Pharmacor, October, 2008

    Atopic dermatitis (AD) is a chronic, relapsing, inflammatory
    skin disorder characterized by flaky, red, and/or lichenified skin lesions,
    intense...

  • Severe Fungal Infections - 2008
    Pharmacor, December, 2008

    Severe fungal infections (SFIs) constitute a highly complex
    market owing to the heterogeneous patient populations at risk, the multiple
    therapeutic...

  • Glioma - 2008
    Pharmacor, December, 2008

    Current therapies for the treatment of glioma are minimally
    effective, and there is an urgent need for effective therapies, especially for
    patients...

  • Erectile Dysfunction - 2009
    Pharmacor, January, 2009

    The vast majority of patients diagnosed with erectile
    dysfunction (ED) and treated for the condition receive pharmacological therapy
    with agents...

  • Acute Heart Failure - 2009
    Pharmacor, February, 2009

    The incidence of acute heart failure (AHF) is increasing,
    owing to the aging of the population, improved methods for diagnosing AHF
    events, and...

  • Age-Related Macular Degeneration - 2009
    Pharmacor, March, 2009

    Following the introduction of anti-vascular endothelial
    growth factor (VEGF) therapies, the age-related macular degeneration (AMD)
    market has seen...

  • Small-Cell Lung Cancer - 2009
    Pharmacor, April, 2009

    Small-cell lung cancer (SCLC) is the most aggressive form of
    lung cancer. When diagnosed, most patients already have extensive disease
    (ED-SCLC), for...

  • Myelodysplastic Syndromes - 2009
    Pharmacor, May, 2009

    The group of bone marrow disorders known as myelodysplastic
    syndromes
    (MDS) is a niche indication with few approved
    therapies. Approval...

  • Treatment Algorithms in Type 2 Diabetes
    Treatment Algorithms, October, 2009

    Treatment for type 2 diabetes centers on effective control of blood glucose to avoid serious and systemic long-term consequences such as...

  • LaunchTrends: ULORIC (Gout)(Wave 3) 2009
    LaunchTrends, October, 2009

  • Treatment Algorithms in Fibromyalgia
    Treatment Algorithms, October, 2009

    The approval of Pfizer’s Lyrica (pregabalin, the first agent approved for fibromyalgia in June 2007), and subsequent approvals of Eli Lilly’s Cymbalta...

  • Rheumatoid Arthritis in India
    Emerging Markets, October, 2009

    India is one of the fastest growing pharmaceutical markets in the world and has a rapidly expanding population of rheumatoid arthritis (RA) patients....

Displaying results 1-20 (of 50)
 |<  < 1 2 3  >  >| 

Search Reports

Decision Resources Group brands include: